Pfizer Drops $119 Billion Bid For AstraZeneca

Your browser doesn’t support HTML5 audio

William Vazquez

It would have been the biggest deal the pharmaceutical industry has seen in more than a decade. But for now, it's off the table.

Pfizer has withdrawn its offer to buy British drug company AstraZeneca for about $119 billion.

American pharmaceutical giant Pfizer, which makes Lipitor and Viagra, has been circling its smaller rival AstraZeneca for months.

AstraZeneca, which makes Nexium and Crestor, has rejected every offer saying Pfizer undervalues the company, and that it wants to remain independent.

There were fears that jobs and research facilities in the UK would be lost.

Had the deal gone through, Pfizer could have reincorporated in Britain and taken advantage of lower taxes.

Inversions as they're called, annoy members of Congress who say they erode the U.S. corporate tax base.

Both companies face stiff competition in the future as more and more people turn to less expensive, generic drugs.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

  • Facebook
  • Twitter
  • LinkedIn
  • Email
  • Flipboard
Elizabeth Blair is a Peabody Award-winning senior producer/reporter on the Arts Desk of NPR News.
Related Content
  1. A world champion didn't start rock climbing until after he lost his sight
  2. Wellspring Health Access is Wyoming's only clinic to provide surgical abortions
  3. Some Wyoming Republicans want to limit the secretary of state after Trump's pick wins
  4. Environmentalists sue after the White House resumed sales of oil and gas leases